POLA2 and glioblastoma: Our data demonstrate that loss of POLA2 results in increased sensitivity to IR and Niraparib (Figure 4), IR being one of the standard GBM therapeutic modalities and Niraparib being the subject of two active and one completed clinical trial (clinicaltrials.gov).